You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 23, 2024

Claims for Patent: 9,399,061

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,399,061

Title:	Methods for determining efficacy of TNF-.alpha. inhibitors for treatment of rheumatoid arthritis
Abstract:	The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNF.alpha. inhibitor, such as a human TNF.alpha. antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNF.alpha. inhibitor for treatment of rheumatoid arthritis in a subject.
Inventor(s):	Kupper; Hartmut (Mutterstadt, DE), Kent; Jeffrey D. (Deerfield, IL), Cifaldi; Mary A. (Gurnee, IL), Perez; John L. (Doylestown, PA), Burmester; Gerd R. (Berlin, DE), Mease; Philip (Seattle, WA), Lovell; Daniel J. (Cincinnati, OH), Keystone; Edward (Toronto, CA), Kavanaugh; Arthur (San Diego, CA)
Assignee:	ABBVIE BIOTECHNOLOGY LTD (Hamilton, BM)
Application Number:	11/786,442
Patent Claims:	1. A method for treating an adult patient having moderate to severe active rheumatoid arthritis (RA), wherein the patient is nonresponsive to treatment with etanercept and infliximab, the method comprising administering 40 mg of adalimumab to the patient every other week to thereby treat the moderate to severe active RA. 2. The method of claim 1, wherein treatment is assessed by an improvement in EULAR score. 3. The method of claim 1, wherein treatment is assessed by achieving an ACR20 response. 4. The method of claim 1, wherein adalimumab is administered to the patient by subcutaneous injection. 5. The method of claim 1, wherein said 40 mg adalimumab is comprised in a pre-filled syringe for subcutaneous injection. 6. The method of claim 1, wherein said 40 mg adalimumab is formulated at a concentration of 50 mg/ml.

Details for Patent 9,399,061

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998	⤷ Try a Trial	2026-04-10
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998	⤷ Try a Trial	2026-04-10
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999	⤷ Try a Trial	2026-04-10
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004	⤷ Try a Trial	2026-04-10
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007	⤷ Try a Trial	2026-04-10
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	09/14/2017	⤷ Try a Trial	2026-04-10
Immunex Corporation	ENBREL	etanercept	Injection	103795		⤷ Try a Trial	2026-04-10
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.